Activity landscape of DNA methyltransferase inhibitors bridges chemoinformatics with epigenetic drug discovery.
BACKGROUND
Activity landscapes are valuable tools for exploring systematically the structure-activity relationships (SAR) of chemical databases. Their application to analyze the SAR of DNA methyltransferase (DNMT) inhibitors, which are attractive compounds as potential epi-drugs or epi-probes, provides useful information to identify pharmacophoric regions and plan the development of predictive models and virtual screening.


METHODS
This paper highlights different approaches for conducting SAR analysis of datasets with a particular focus on the activity landscape methodology. SAR information of DNMT inhibitors (DNMTi), stored in a public database, is surveyed to further illustrate concepts and generalities of activity landscape modeling with a special emphasis on structure-activity similarity (SAS) maps.


CONCLUSIONS
The increasing SAR information reported for DNMTi opens up avenues to implement activity landscape methods. Despite several activity landscape methods, such as SAS maps, being well established, these need further refinement. For instance, novel combinations of multiple representations, such as the addition of Z-values of similarity (fusion-Z), lead to more robust representations of consensus SAS maps. Density SAS maps improve the visualization of the SAR. A survey of activity cliffs (i.e., pairs of compounds with high structural similarity but high differences in potency) of DNMTi available in a public database suggest that it is feasible to develop predictive models for non-nucleoside DNMTi using approaches such as quantitative structure-activity relationships and that non-nucleoside DNMTi in ChEMBL can be used as query molecules in similarity-based virtual screening.
a 1 Universidad Nacional Autónoma de México, Departamento de Farmacia, Facultad de Química , Avenida Universidad 3000, Mexico City, D.F. 04510, México +5255 5622 3899 Ext. 44458 ; medinajl@unam.mx ; jose.medina.franco@gmail.com.|b 2 Universidad Nacional Autónoma de México, PECEM, Facultad de Medicina , Avenida Universidad 3000, Mexico City, D.F. 04510, México.
J Jesús
JJ
Naveja
a 1 Universidad Nacional Autónoma de México, Departamento de Farmacia, Facultad de Química , Avenida Universidad 3000, Mexico City, D.F. 04510, México +5255 5622 3899 Ext. 44458 ; medinajl@unam.mx ; jose.medina.franco@gmail.com.
José L
JL
Medina-Franco
D019295:Computational Biology; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors*; D015195:Drug Design; D055808:Drug Discovery / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D057890:Epigenomics / Q000379:methods; D006801:Humans; D008958:Models, Molecular; D013329:Structure-Activity Relationship
D004791:Enzyme Inhibitors; D004248:DNA (Cytosine-5-)-Methyltransferases
DNA methyltransferase; activity cliffs; cancer; data mining; epi-informatics; structure-activity relationships